Latest Commercialisation Strategies News

Provaris Energy has launched a capital-lite revenue model designed to generate early cash flow with minimal capital expenditure, alongside securing a major hydrogen supply agreement with Uniper Global Commodities. The company targets first hydrogen deliveries by early 2029, advancing its position in Europe's hydrogen supply chain.

Neurizon Therapeutics has been granted a pivotal US patent for its lead drug candidate NUZ-001, extending protection until 2039 and enhancing its commercial and clinical positioning in neurodegenerative disease treatment.

Calix Limited has successfully closed its Share Purchase Plan, raising $2.1 million to complement a prior $20 million institutional placement, strengthening its balance sheet to advance key environmental technology projects.

Dreadnought Resources reports robust exploration results including high-grade gold at Mangaroon and niobium at Gifford Creek, alongside new joint ventures and asset sales that position the company for growth.

Vectus Biosystems reports completion of Phase Ib trials for its lead drug VB0004 and a robust cash position bolstered by a significant R&D tax refund, setting the stage for licensing discussions.

Earth's Energy Limited reports promising progress in its Paralana and Flinders West geothermal projects, confirming new development zones and initiating joint venture discussions, while maintaining a solid cash position.

First Graphene has secured an additional AUD$404,300 R&D tax rebate for significant manufacturing process improvements at its Henderson facility, complementing a recent AUD$166,000 rebate from UK-based research efforts.

Artrya Limited reports solid progress on its FDA 510(k) application and secures a A$5 million capital raise, positioning itself for imminent commercial rollout in the US healthcare sector.

Respiri Limited reports a standout December quarter marked by a 67% surge in patient program enrolments and robust revenue growth, bolstered by strategic acquisition synergies from Orb Health. The company is poised for further expansion in 2025 amid promising contract negotiations and evolving US healthcare reimbursement policies.

Biotron Limited has engaged US-based C14 Consulting Group to drive strategic partnerships for its antiviral drug portfolio, including lead candidate BIT225, while advancing its Hepatitis B research.

Firebrick Pharma has made notable progress expanding its Nasodine nasal spray in Singapore, securing major distribution and marketing agreements that set the stage for retail sales growth in 2025.

Zoono Group reports expanding global trials of its shelf-life extension technology, engaging over 40 supermarket and packaging companies, while refining its product and managing cash flow amid cautious commercial adoption.